amifampridine
Sign in to saveAmifampridine phosphate is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and approved by the FDA for Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477217342
- Drug.image
- Diaminopyridine.png
- Drug.image_class
- skin-invert-image
- Drug.width
- 120
- Drug.image2
- 3,4-diaminopyridine-3D-balls.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Firdapse, Ruzurgi
- Drug.DailyMedID
- Amifampridine
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N07
- Drug.ATC_suffix
- XX05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
425 papers- Amifampridine.2006
- Amifampridine.2012
- Amifampridine for Lambert-Eaton myasthenic syndrome.Australian prescriber · 2022
- Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.Expert review of clinical immunology · 2019
- Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.Expert review of clinical pharmacology · 2019
via PubMed
Article
11 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Research
- References
Amifampridine phosphate is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and approved by the FDA for Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form.
Around 2000 doctors at Assistance Publique – Hôpitaux de Paris created a phosphate salt form, which was developed through a series of companies ending with BioMarin Pharmaceutical which obtained European approval in 2009 under the brand name Firdapse, and which licensed the US rights to Catalyst Pharmaceuticals in 2012. As of January 2017, Catalyst and another US company, Jacobus Pharmaceutical, which had been manufacturing and giving it away for free since the 1990s, were both seeking FDA approval for their iterations and marketing rights.
Connections
Categories
3-Aminopyridines4-AminopyridinesChemical articles with multiple CAS registry numbersChemicals using indexlabelsDiaminesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs with non-standard legal statusECHA InfoCard ID from WikidataMultiple chemicals in Infobox drugOrphan drugsPotassium channel blockers